TY - JOUR
T1 - SNX9 determines the surface levels of integrin β1 in vascular endothelial cells
T2 - Implication in poor prognosis of human colorectal cancers overexpressing SNX9
AU - Tanigawa, Kazufumi
AU - Maekawa, Masashi
AU - Kiyoi, Takeshi
AU - Nakayama, Jun
AU - Kitazawa, Riko
AU - Kitazawa, Sohei
AU - Semba, Kentaro
AU - Taguchi, Tomohiko
AU - Akita, Satoshi
AU - Yoshida, Motohira
AU - Ishimaru, Kei
AU - Watanabe, Yuji
AU - Higashiyama, Shigeki
N1 - Funding Information:
The authors thank Ms. Ayako Fujisaki, Ms. Mami Chosei, Ms. Yuki Tanaka, Dr. Tomohisa Sakaue, Dr. Shinji Fukuda, Dr. Hirotaka Takahashi, Dr. Hiroyuki Takeda, and Dr. Tatsuya Sawasaki (Ehime University) for their technical assistance. This study was supported by JSPS KAKENHI grant number JP18K16317 to K. T. and JP18K15244, YOKOYAMA Foundation for Clinical Pharmacology 2017 (YRY-1703) to MM and JSPS KAKENHI grant number JP16H046980 to S. H. This investigation was supported in parts by The Mochida Memorial Foundation for Medical and Pharmaceutical Research to M.M.
Funding Information:
The authors thank Ms. Ayako Fujisaki, Ms. Mami Chosei, Ms. Yuki Tanaka, Dr. Tomohisa Sakaue, Dr. Shinji Fukuda, Dr. Hirotaka Takahashi, Dr. Hiroyuki Takeda, and Dr. Tatsuya Sawasaki (Ehime University) for their technical assistance. This study was supported by JSPS KAKENHI grant number JP18K16317 to K. T. and JP18K15244, YOKOYAMA Foundation for Clinical Pharmacology 2017 (YRY‐1703) to MM and JSPS KAKENHI grant number JP16H046980 to S. H. This investigation was supported in parts by The Mochida Memorial Foundation for Medical and Pharmaceutical Research to M.M.
Funding Information:
YOKOYAMA Foundation for Clinical Pharmacology, Grant/Award Number: Research Grant 2017 (YRY‐1703) to MM; JSPS, Grant/Award Numbers: KAKENHI/ JP18K16317 to KT, KAKENHI/JP16H046980 to SH, KAKENHI/JP18K15244 to MM
Publisher Copyright:
© 2019 The Authors. Journal of Cellular Physiology Published by Wiley Periodicals, Inc.
PY - 2019/10
Y1 - 2019/10
N2 - Angiogenesis, the formation of new blood vessels, is involved in a variety of diseases including the tumor growth. In response to various angiogenic stimulations, a number of proteins on the surface of vascular endothelial cells are activated to coordinate cell proliferation, migration, and spreading processes to form new blood vessels. Plasma membrane localization of these angiogenic proteins, which include vascular endothelial growth factor receptors and integrins, are warranted by intracellular membrane trafficking. Here, by using a siRNA library, we screened for the sorting nexin family that regulates intracellular trafficking and identified sorting nexin 9 (SNX9) as a novel angiogenic factor in human umbilical vein endothelial cells (HUVECs). SNX9 was essential for cell spreading on the Matrigel, and tube formation that mimics in vivo angiogenesis in HUVECs. SNX9 depletion significantly delayed the recycling of integrin β1, an essential adhesion molecule for angiogenesis, and reduced the surface levels of integrin β1 in HUVECs. Clinically, we showed that SNX9 protein was highly expressed in tumor endothelial cells of human colorectal cancer tissues. High-level expression of SNX9 messenger RNA significantly correlated with poor prognosis of the patients with colorectal cancer. These results suggest that SNX9 is an angiogenic factor and provide a novel target for the development of new antiangiogenic drugs.
AB - Angiogenesis, the formation of new blood vessels, is involved in a variety of diseases including the tumor growth. In response to various angiogenic stimulations, a number of proteins on the surface of vascular endothelial cells are activated to coordinate cell proliferation, migration, and spreading processes to form new blood vessels. Plasma membrane localization of these angiogenic proteins, which include vascular endothelial growth factor receptors and integrins, are warranted by intracellular membrane trafficking. Here, by using a siRNA library, we screened for the sorting nexin family that regulates intracellular trafficking and identified sorting nexin 9 (SNX9) as a novel angiogenic factor in human umbilical vein endothelial cells (HUVECs). SNX9 was essential for cell spreading on the Matrigel, and tube formation that mimics in vivo angiogenesis in HUVECs. SNX9 depletion significantly delayed the recycling of integrin β1, an essential adhesion molecule for angiogenesis, and reduced the surface levels of integrin β1 in HUVECs. Clinically, we showed that SNX9 protein was highly expressed in tumor endothelial cells of human colorectal cancer tissues. High-level expression of SNX9 messenger RNA significantly correlated with poor prognosis of the patients with colorectal cancer. These results suggest that SNX9 is an angiogenic factor and provide a novel target for the development of new antiangiogenic drugs.
KW - angiogenesis
KW - colorectal cancer
KW - endothelial cells
KW - integrin β1
KW - sorting nexin 9
UR - http://www.scopus.com/inward/record.url?scp=85061920973&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85061920973&partnerID=8YFLogxK
U2 - 10.1002/jcp.28346
DO - 10.1002/jcp.28346
M3 - Article
C2 - 30784076
AN - SCOPUS:85061920973
SN - 0021-9541
VL - 234
SP - 17280
EP - 17294
JO - Journal of Cellular Physiology
JF - Journal of Cellular Physiology
IS - 10
ER -